**VRIJDAG 15 februari 2019**

|  |  |
| --- | --- |
| 16:00 – 16:30 | **Ontvangst en registratie** |
| 16:30 – 16:45 | **Welkom en opening**  **Chairs:** Erik Cornel (ivm mogelijke afwezigheid op zaterdag) &  - Toelichting op het programma en selectie van de sessies uit   het ASCO-GU programma.  - Toelichting op het interactieve live programma met San Francisco |
| 16:45 – 18:00 | **Onderwerp: prostaatkanker**  **Chairs:** Erik Cornel (ivm mogelijke afwezigheid op zaterdag) &  **General Session 1: Optimizing Diagnosis and Treatment of Clinically Significant Nonmetastatic Prostate Cancer**  **[20 min]** *Update on Prostate-Specific Antigen Screening*   * Andrew Vickers, PhD   Memorial Sloan Kettering Cancer Center  **General Session 2: General Session 2: Quality, Value, and Science for Optimizing Advanced Prostate**  **Beyond Survival: Clinical Decision Making for Castrate-Sensitive Prostate Cancer**  **[20 min]** *Biologic Basis for Sequencing Novel Treatments for Metastatic Prostate Cancer*   * Himisha Beltran, MD   Dana Farber Cancer Institute  **[20 min]** *Practical Application of Genomic Assays in Clinical Decision Making*   * Mark Rubin, * University of Bern   **[15 min] Discussie & casus** |
| 18:00 – 18:15 | **Pauze** |
| 18:15 – 19:45 | **Onderwerp:**  **Chair:**  **Oral Abstract Session A/Rapid Abstract Session A**  **[15 min]**  **[15 min]**  **[15 min]**  **[15 min]**  **[15 min]**  **[30 min] Discussie & voorbereiding voor de live sessie** |
| 19:45 – 20:45 | **Diner** |
| 20:45 – 21:00 | **Terugkeer naar de zaal voor de live sessie** |
| 21:00 – 21:30 | **Individual live session with San Francisco**  Gasten:  Moderator: |

**Zaterdag 10 februari 2018**

|  |  |
| --- | --- |
| 08:15 -08:30 | **Welkom en opening dag 2**  **Chair:** |
| 08:30 – 10:45 | **Onderwerp: Blaaskanker**  **Chair:**  **General Session 4: Challenges and Advances in Perioperative therapy for urothelial cancer**  **[20 min]** *Genomic Insights and Biomarkers for Treatment Selection in Muscle-Invasive and Non-Muscle-Invasive Bladder Cancer*   * Yair Lotan, MD – * The University of Texas Southwestern Medical Center   **[20 min]** *Challenges of Therapy in Upper-Tract Urothelial Carcinoma*   * Surena F. Matin, MD, FACS – * University of Texas MD Anderson Cancer Center   **[15 min]** *Abstract*   * First Author:   **[15 min] Discussie/abstract**  **[15 min]** *Abstract*   * First Author:   **[15 min]** *Abstract*   * First Author:   **[30 min]** **Discussie en toelichting** |
| 10:45 -11:00 | **Pauze** |
| 11:00 - 12:45 | **Onderwerp: Blaaskanker**  **Chair:**  **Debate: The Optimal Local Treatment for Muscle-Invasive Bladder Cancer**  **[15 min]** *Radical Cystectomy Is the Best Option for Muscle-Invasive Bladder Cancer*   * Michael Cookson, MD – * University of Oklahoma Health Sciences Center   **[15 min]** *Trimodality Therapy Is the Best Option for Muscle-Invasive Bladder Cancer*   * **Jason A. Efstathiou, MD, Dphil –** * **Massachusetts General Hospital**   **Keynote lecture**  **[45 min]** *Immunotherapy Across Genitourinary Malignancies*   * James L. Gulley, MD, PhD, FACP – * National Cancer Institute   **[10 min]** *Abstract*   * First Author:   **[20 min] Discussie** |
| 12:45 – 13:30 | **Lunch** |
| 13:30 – 14:15 | **Introductie & bekijken opgenomen sessie vanuit San Francisco**  **Onderwerp:**  Gasten:  Moderator: |
| 14:15 – 15:30 | **Onderwerp: Blaaskanker & overig**  **Chair:**  **[15 min]** *Abstract*   * First Author:   **[15 min]** *Abstract*   * First Author:   **[15 min]** *Abstract*   * First Author:   **[15 min]** *Abstract*   * First Author:   **[15 min] Discussie** |
| 15:30 – 16:00 | **Wrap-up en afsluiting**  **Chair:** |

Reserve:

General Session 1: Optimizing Diagnosis and Treatment of Clinically Significant Nonmetastatic Prostate Cancer

**20 min** *Advanced Imaging and Biomarkers*

* Felix Y Feng, MD –
* University of California, San Francisco

General Session 4: Challenges and Advances in Perioperative therapy for urothelial cancer

**20 min** *Perioperative Immunotherapy in Urothelial Carcinoma: State of Existing Evidence*

* Andrea Necchi, MD - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori

Een deel uit deze sessie; (is 1,5 uur, maar bijv. 30 minuten casus 1 of 2, op basis van scouting)

|  |  |
| --- | --- |
| General Session 5: Multimodality Treatment in Challenging Cases of urothelial carcinoma |  |
|  | Ananya Choudhury, MA, PhD, MRCP, FRCR—Chair - The Christie NHS Foundation Trust and University of Manchester |
|  | Brant Allen Inman, MD—Chair - Duke University Medical Center |
| Case Panel Discussion |  |
|  | Robert A. Huddart, MBBS, MRCP, FRCR, PhD - The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust - Radiation Oncologist |
|  | Matt D. Galsky, MD - Icahn School of Medicine at Mount Sinai - Medical Oncologist |
|  | Eila C. Skinner, MD - Stanford University - Urologist |
|  | Valeria Panebianco, MD - Sapienza University of Rome - Radiologist |